Investment
Features
FeesSafety
Academy
More
Pluang+

Compare eBay Inc (EBAY) vs Gilead Sciences, Inc. (GILD) Price & Performance

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

eBay Inc vs Gilead Sciences, Inc. — how do they compare? eBay Inc trades at $103.68 (market cap $47.17B), while Gilead Sciences, Inc. trades at $136.41 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 3.6× eBay Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

EBAYGILD
Market Cap
$47.17B$168.35B
Volume
5,186,418
Sector
Consumer CyclicalHealth
52-Week High
$118.96$155.80
52-Week Low
$79.41$110.56
Enterprise Value
$51.00B$191.42B
Dividend Yield
1.17%2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

eBay Inc

EBAY trades at $107.71, down 3.81% on news that GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock shows bearish technical signals but maintains strong fundamentals with 18.57% net margins and consistent earnings beats. Recent Q2 results exceeded expectations with 14% GMV growth, though insider selling and takeover uncertainty create near-term pressure.

EBAY offers solid fundamentals with improving revenue guidance and attractive valuation multiples, but faces significant event risk from the potential GameStop deal collapse. The 11% upside to consensus price target suggests moderate bullish sentiment, though investors should monitor partnership developments and Q3 earnings for directional clarity.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About eBay Inc

eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.

Read more on EBAY

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD